704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III

High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time

Prophylactic dexamethasone to reduce risk of cilta cel associated immune effector cell delayed neurotoxicity

Increased alemtuzumab exposure correlates with improved responses in heavily pretreated R R ALL patients Analysis of the balli 01 trial

Administration of off the shelf expanded most closely HLA matched third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients

First in human Phase I study of autologous CD5 knockout anti CD5 CAR T cells in CD5 hematologic malignancies

Unveiling the second wave Viral triggered biphasic CAR T expansion drives late onset IEC HS Characterization and successful management

Point of care anti CD19 CAR T for autoimmune diseases

CCR5 blockade A therapeutic approach to uncouple CART BCMA expansion from CART mediated immune toxicities

MT 601 demonstrates favorable safety and durable responses in relapsed or refractory r r non Hodgkin lymphoma NHL

Defining a high risk population for CAR T cell therapy The impact of clonal hematopoiesis and pre existing neutropenia on severe outcomes in patients treated for malignant and non malignant conditions

Donor derived secondary CAR T cell therapy for relapsed leukemia following initial CAR T bridged to allogeneic transplantation Efficacy and safety analysis

Donor derived CAR T cells co infused with the allogenic graft on the platform of T cell depletion or post transplant cyclophosphamide in children with advanced B cell neoplasms

Long term follow up autologous CD30 CAR T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy

Torque teno virus in pediatric CAR T recipients

Safety and efficacy of less differentiated CAR T cell products in relapsed refractory B cell non Hodgkin lymphomas A meta analysis

Lipo MIT based bridging therapy enables effective CAR T treatment in high risk relapsed or refractory B cell lymphoma

A tandem bispecific nanobody CAR SL1703 T cells targeting CD19 BCMA for refractory or relapsed multiple myeloma as salvage treatment after BCMA CAR T therapy failure

Novel bispecific epitope anti CD5 nanobody CAR T cells for refractory or relapsed T cell malignancies

Impact of clonal hematopoiesis on hematologic recovery and outcomes following tumor infiltrating lymphocyte therapy

Long term remission and survival in patients with relapsed or refractory non Hodgkin lymphoma after treatment of brl 201 a CRISPR based non viral PD 1 locus specifically integrated anti CD19 CAR T cells 4 year follow up of a first in human phase I study

Autologous hematopoietic stem cell transplantation combined with inaticabtagene autoleucel in adults with high risk B cell acute lymphoblastic leukemia Interim analysis of a phase II study

Impact and predictors of icans on survival in lymphoma and myeloma patients treated with CAR T cell therapy

Allogeneic induced pluripotent stem cell derived invariant natural killer T cell therapy A phase 1 clinical Trial

Unsupervised proteomic and metabolomic longitudinal serum profiling of anti CD19 CAR T cell therapy recipients reveals clinically distinct groups

Phase 1 clinical trial of point of care manufactured fully human anti CD19 CAR T cells for treatment of Relapsed Refractory lymphoid malignancies

Autologous hematopoietic stem cell transplantation followed by CD19 CD22 dual target CAR T therapy for refractory or relapsed burkitt lymphoma

Glofitamab for patients with Non–Large B cell lymphoma refractory or relapsing after anti CD19 CAR T cell therapy Final bicar study LYSA results